-
1 Comment
RaQualia Pharma Inc is currently in a long term downtrend where the price is trading 4.6% below its 200 day moving average.
From a valuation standpoint, the stock is 72.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.7.
RaQualia Pharma Inc's total revenue sank by 46.3% to $534M since the same quarter in the previous year.
Its net income has dropped by 82.9% to $92M since the same quarter in the previous year.
Finally, its free cash flow fell by 6032.0% to $-260M since the same quarter in the previous year.
Based on the above factors, RaQualia Pharma Inc gets an overall score of 1/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| ISIN | JP3967150008 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 1200 |
|---|---|
| PE Ratio | None |
| Beta | 0.65 |
| Market Cap | 10B |
| Dividend Yield | None |
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. The company also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; RQ-00317076 for pain; and RQ-00000010 for gut motility disorders, gastroparesis, functional dyspepsia, and chronic constipation. In addition, it provides RQ-00433412 for constipation, and cancer-related anorexia/cachexia syndrome; RQ-00000009 to treat alzheimer's; RQ-00466479, RQ-00350215, and RQ-00434739 to treat chronic pain; RQ-00310941 to treat D-IBS, IBD-remission stage symptoms; RQ-00201894 for gastroparesis, functional dyspepsia, and post-operative ileus; tamibarotene to treat higher-risk myelodysplastic syndrome and acute myeloid leukemia; and FIM-001 for cancer. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4579.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
